bimagrumab semaglutide The future is coming. The phase 2 results of (a drug that blocks our muscle growth slowing mechanism BELIEVE study assessing bimagrumab for

Personalized hormone therapy, medical weight loss, peptides, IV therapy, and primary care in Colorado Springs

GLP-1 receptor agonists are designed for weight management, not thyroid treatment

Just a few years ago, semaglutide changed the obesity and diabetes market

Women benefit most when we treat menopause as the metabolic inflection point it isnot just prescribing GLP-1s in isolation, but considering hormone therapy, addressing sleep disruption (which drives cortisol and undermines any weight loss effort), and building strength to counter the lean mass loss these medications can cause

FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs Eli Lilly and Co.s Zepbound (tirzepatide) and Novo Nordisk A/S Saxenda (liraglutide) and Wegovy (semaglutide).